Several drug classes under evaluation, or recently approved, for the treatment of MASLD, may increase fracture risk, including thiazolidinediones, glucagon-like peptide analogs, and FGF-21 analogs. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.